---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093951"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:59:04.458553+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Crinetics Q2 net loss $74.1M; CFO Wilson departs; paltusotine NDA on track for H2 2024

## Summary
- Net loss of $74.1M in Q2 2024 vs $51.0M in Q2 2023; R&D expenses rose to $58.3M from $40.6M.
- CFO Marc Wilson stepping down for personal reasons; search for successor initiated; he will remain until replacement on-boarded.
- Paltusotine NDA for acromegaly on track for H2 2024; Phase 3 program for carcinoid syndrome expected to begin by end of 2024.
- Topline data from atumelnant Phase 2 studies in CAH and Cushing's syndrome anticipated by end of 2024.
- Unrestricted cash $863M as of June 30, 2024; management expects funding into 2028.

## SEC filing metadata
- accession: 0000950170-24-093951
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017024093951/0000950170-24-093951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017024093951/crnx-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093951
- JSON: https://secwatch.observer/filing/0000950170-24-093951.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093951.txt

## Key facts
- Executive change
  Marc Wilson departed as Chief Financial Officer at Crinetics Pharmaceuticals, Inc..
  - Action: stepped down
  - Role: Chief Financial Officer
  source text: On August 5, 2024, Marc Wilson notified the Company of his decision to step down from his position as Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000095017024093951/0000950170-24-093951-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.